XCUR - EXICURE, INC.

4.15
0.160   3.855%

Share volume: 6,937
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$3.99
0.16
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
14.64%
1 Month
-5.47%
3 Months
-22.14%
6 Months
-3.49%
1 Year
-64.22%
2 Year
538.46%
Key data
Stock price
$4.15
P/E Ratio 
0.00
DAY RANGE
$4.03 - $4.26
EPS 
-$3.82
52 WEEK RANGE
$3.10 - $15.91
52 WEEK CHANGE
-$61.21
MARKET CAP 
25.840 M
YIELD 
N/A
SHARES OUTSTANDING 
6.374 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
06-16-2025
BETA 
5.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,326
AVERAGE 30 VOLUME 
$23,634
Company detail
CEO: Matthias G. Schroff
Region: US
Website: exicuretx.com
Employees: 50
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Exicure, Inc. develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders.

Recent news